---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002037"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:46:20.826412+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Regeneron reports preliminary Q4 U.S. EYLEA HD sales of $123M; IPR&D charge of $30M

## Summary
- Preliminary Q4 2023 U.S. net product sales: EYLEA HD $123M, EYLEA $1.34B, combined $1.46B.
- Acquired IPR&D charge of $30M pre-tax from Intellia collaboration extension, reducing GAAP and non-GAAP EPS by ~$0.21.
- Dupixent global net sales through 9M 2023: ~$8.4B, up 34% YoY; pivotal COPD data supports 2024 launch potential.
- EYLEA HD FDA-approved August 2023 for wAMD, DME, DR; ~2/3 of eligible lives covered, permanent J-code expected April 1, 2024.
- Oncology pipeline: BLAs submitted for odronextamab (B-NHL) and linvoseltamab (MM); potential for up to three FDA approvals by end of 2024.

## SEC filing metadata
- accession: 0001104659-24-002037
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465924002037/0001104659-24-002037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465924002037/tm242296d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002037
- JSON: https://secwatch.observer/filing/0001104659-24-002037.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002037.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported fourth quarter 2023 results: EPS $0.21.
  - Period: fourth quarter 2023
  - EPS: $0.21
  - Result: preliminary results
  source text: the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® HD (aflibercept) Injection 8 mg of approximately $123 million and the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $1.34 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465924002037/0001104659-24-002037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.